TransMedics Group (TMDX:NASDAQ) Annual Reports & Investor Relations Material

Overview

TransMedics Group, Inc. is a medical technology company that is revolutionizing organ transplant therapy for patients suffering from end-stage organ failure. This commercial-stage company offers its proprietary Organ Care System (OCS) that aims to replicate near-physiologic conditions for donor organs outside of the human body. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes the company's customized technology. The OCS system has various tools, such as the OCS LUNG, the OCS Heart, and the OCS Liver, which cater to the preservation and improvement of the quality of donor organs. Their OCS Lung is for the preservation of standard criteria donor lungs to prepare for double-lung transplantation, while the OCS Heart is designed for the preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage. TransMedics' OCS Liver, on the other hand, is for the preservation of donor livers. Founded in 1998, the company's headquarters is based in Andover, Massachusetts.

Frequently Asked Questions

What is TransMedics Group's ticker?

TransMedics Group's ticker is TMDX

What exchange is TransMedics Group traded on?

The company's shares trade on the NASDAQ stock exchange

Where are TransMedics Group's headquarters?

They are based in Andover, Massachusetts

How many employees does TransMedics Group have?

There are 51-200 employees working at TransMedics Group

What is TransMedics Group's website?

It is transmedics.com

What type of sector is TransMedics Group?

TransMedics Group is in the Healthcare sector